CapsoVision, Inc.
CV
Get informed when a big investor buys or sells
+ FollowMarket Cap$330.26M
Close$
$-2.25
134.7% downside
Current Fair Value
134.7% downsideOvervalued by 134.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $330.26 Million |
|---|---|
| Enterprise Value | $313.20 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.03 |
| Beta | -2.79 |
| Outstanding Shares | 47,456,908 |
Return
| Return on Equity | -133.40% |
|---|---|
| Return on Assets | -103.96% |
| Return on Invested Capital | -84.04% |
Valuation & Multiples
| P/E Ratio | -6.3 |
|---|---|
| PEG | -20.41 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 23.09 |
| Enterprise Value to EBIT | -18.11 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 3, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$3.59 M
Average shareholder expectationNext Earnings Call
Expected Date
June 25, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$3.81 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.63%▼ 0.03% |
|---|---|
| Total Invested | $29.12M▲ 255.22% |
| Investors Holding | 50▲ 19.00% |
ESG Score
No data
About CapsoVision, Inc.
90 employees
CEO: Kang Huai Wang Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics